Latest news
Phase II Research Against Covid-19 Launched in France with Debiopharm’s Antiviral Alisporivir
Debiopharm International SA and Solid Biosciences, LLC, announce a collaboration to explore the use of Alisporivir (Debio 025) in muscular…
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 – A potent, first-in-class antiviral…
Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb study after record time patient randomisation
Clinical Update – Debio 025 in Hepatitis C – Debiopharm presents promising phase IIa results showing potent antiviral activity
Clinical Update – Debio 025 in Hepatitis C – Debiopharm starts phase IIb triple therapy study, a promising therapeutic avenue
Clinical Update – Debio 025 in Hepatitis C – Presentation of Phase IIa Efficacy Results
Clinical update – Debio 025 cyclophilin inhibitor for the treatment of HCV – A unique viral kinetics